相似文献
1
Yellow fever virus replicons as an expression system for hepatitis C virus structural proteins.
J Virol. 2003 Jan;77(2):1644-8. doi: 10.1128/jvi.77.2.1644-1648.2003.
2
Yellow fever 5' noncoding region as a potential element to improve hepatitis C virus production through modification of translational control.
Biochem Biophys Res Commun. 1998 Dec 18;253(2):257-64. doi: 10.1006/bbrc.1998.9740.
3
Trans-encapsidation of hepatitis C virus subgenomic replicon RNA with viral structure proteins.
Biochem Biophys Res Commun. 2008 Jul 4;371(3):446-50. doi: 10.1016/j.bbrc.2008.04.110. Epub 2008 Apr 28.
4
Construction and applications of yellow fever virus replicons.
Virology. 2005 Jan 20;331(2):247-59. doi: 10.1016/j.virol.2004.10.034.
5
Fine mapping of a cis-acting sequence element in yellow fever virus RNA that is required for RNA replication and cyclization.
J Virol. 2003 Feb;77(3):2265-70. doi: 10.1128/jvi.77.3.2265-2270.2003.
6
Hairpin ribozymes in combination with siRNAs against highly conserved hepatitis C virus sequence inhibit RNA replication and protein translation from hepatitis C virus subgenomic replicons.
FEBS J. 2005 Nov;272(22):5910-22. doi: 10.1111/j.1742-4658.2005.04986.x.
7
Expression of hepatitis C virus (HCV) structural proteins in trans facilitates encapsidation and transmission of HCV subgenomic RNA.
J Gen Virol. 2009 Apr;90(Pt 4):833-842. doi: 10.1099/vir.2008.006049-0. Epub 2009 Feb 17.
8
Comparison of the nucleotide and deduced amino acid sequences of the structural protein genes of the yellow fever 17DD vaccine strain from Senegal with those of other yellow fever vaccine viruses.
Vaccine. 1993;11(6):679-81. doi: 10.1016/0264-410x(93)90317-q.
9
Replicon-helper systems from attenuated Venezuelan equine encephalitis virus: expression of heterologous genes in vitro and immunization against heterologous pathogens in vivo.
Virology. 1997 Dec 22;239(2):389-401. doi: 10.1006/viro.1997.8878.
10
trans-Complementation of yellow fever virus NS1 reveals a role in early RNA replication.
J Virol. 1997 Dec;71(12):9608-17. doi: 10.1128/JVI.71.12.9608-9617.1997.
引用本文的文献
1
Development of a Noninfectious Japanese Encephalitis Virus Replicon for Antiviral Drug Screening and Gene Function Studies.
Viruses. 2025 May 27;17(6):759. doi: 10.3390/v17060759.
2
Amplifying mRNA vaccines: potential versatile magicians for oncotherapy.
Front Immunol. 2023 Oct 23;14:1261243. doi: 10.3389/fimmu.2023.1261243. eCollection 2023.
3
Self-Replicating RNA Viruses for Vaccine Development against Infectious Diseases and Cancer.
Vaccines (Basel). 2021 Oct 15;9(10):1187. doi: 10.3390/vaccines9101187.
4
Self-Amplifying RNA Viruses as RNA Vaccines.
Int J Mol Sci. 2020 Jul 20;21(14):5130. doi: 10.3390/ijms21145130.
5
RNA Viruses as Tools in Gene Therapy and Vaccine Development.
Genes (Basel). 2019 Mar 1;10(3):189. doi: 10.3390/genes10030189.
6
Self-Replicating RNA Viruses for RNA Therapeutics.
Molecules. 2018 Dec 13;23(12):3310. doi: 10.3390/molecules23123310.
7
New frontiers in oncolytic viruses: optimizing and selecting for virus strains with improved efficacy.
Biologics. 2018 Feb 9;12:43-60. doi: 10.2147/BTT.S140114. eCollection 2018.
8
Replicon RNA Viral Vectors as Vaccines.
Vaccines (Basel). 2016 Nov 7;4(4):39. doi: 10.3390/vaccines4040039.
9
Incorporation of hepatitis C virus E1 and E2 glycoproteins: the keystones on a peculiar virion.
Viruses. 2014 Mar 11;6(3):1149-87. doi: 10.3390/v6031149.
10
Identification and characterization of the host protein DNAJC14 as a broadly active flavivirus replication modulator.
PLoS Pathog. 2011 Jan 13;7(1):e1001255. doi: 10.1371/journal.ppat.1001255.
本文引用的文献
1
Mutations in the yellow fever virus nonstructural protein NS2A selectively block production of infectious particles.
J Virol. 2002 May;76(10):4773-84. doi: 10.1128/jvi.76.10.4773-4784.2002.
2
Hepatitis C virus-like particle morphogenesis.
J Virol. 2002 Apr;76(8):4073-9. doi: 10.1128/jvi.76.8.4073-4079.2002.
3
Persistent and transient replication of full-length hepatitis C virus genomes in cell culture.
J Virol. 2002 Apr;76(8):4008-21. doi: 10.1128/jvi.76.8.4008-4021.2002.
4
Selectable subgenomic and genome-length dicistronic RNAs derived from an infectious molecular clone of the HCV-N strain of hepatitis C virus replicate efficiently in cultured Huh7 cells.
J Virol. 2002 Mar;76(6):2997-3006. doi: 10.1128/jvi.76.6.2997-3006.2002.
5
Biogenesis of hepatitis C virus envelope glycoproteins.
J Gen Virol. 2001 Nov;82(Pt 11):2589-2595. doi: 10.1099/0022-1317-82-11-2589.
6
Construction, safety, and immunogenicity in nonhuman primates of a chimeric yellow fever-dengue virus tetravalent vaccine.
J Virol. 2001 Aug;75(16):7290-304. doi: 10.1128/JVI.75.16.7290-7304.2001.
7
Essential role of cyclization sequences in flavivirus RNA replication.
J Virol. 2001 Jul;75(14):6719-28. doi: 10.1128/JVI.75.14.6719-6728.2001.
8
E2-p7 region of the bovine viral diarrhea virus polyprotein: processing and functional studies.
J Virol. 2000 Oct;74(20):9498-506. doi: 10.1128/jvi.74.20.9498-9506.2000.
9
Chimeric yellow fever/dengue virus as a candidate dengue vaccine: quantitation of the dengue virus-specific CD8 T-cell response.
J Virol. 2000 Sep;74(17):8094-101. doi: 10.1128/jvi.74.17.8094-8101.2000.
10
Charged residues in the transmembrane domains of hepatitis C virus glycoproteins play a major role in the processing, subcellular localization, and assembly of these envelope proteins.
J Virol. 2000 Apr;74(8):3623-33. doi: 10.1128/jvi.74.8.3623-3633.2000.
Zotero 插件